Engineered Tissue Solutions

Engineered Tissue Solutions (ETS) is a US-based wound care company headquartered in Rolla, Missouri, specializing in bioactive glass fiber matrices for chronic and surgical wound management. The company manufactures and markets Mirragen®, a proprietary borate-based bioactive glass wound matrix positioned as an alternative to traditional tissue-based products, eliminating infection risk while facilitating tissue formation. ETS offers two primary product lines: Mirragen Advanced Wound Care for chronic wound management (including diabetic foot ulcers) and MirraSurg for complex surgical wounds. The company has published two randomized controlled trials demonstrating clinical efficacy and has received Technology Breakthrough designation from Premier, Inc. ETS was acquired by Heraeus Group (a diversified family-owned technology company) in 2021 and maintains US-based manufacturing and innovation operations. The company distributes through major group purchasing organizations (GPOs) including Vizient and serves acute care hospitals, wound centers, and surgical facilities. Clinical evidence includes RCT data on DFU outcomes and ongoing gene expression research partnerships. All manufacturing, R&D, and headquarters operations are conducted in the United States. The company maintains compliance with medical device regulations and participates in industry standards for wound care product marketing and reimbursement.